b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">31423707</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>16</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1476-4431</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>29</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Sep</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)</Title>\n                <ISOAbbreviation>J Vet Emerg Crit Care (San Antonio)</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Successful management of acute bilirubin encephalopathy in a dog with immune-mediated hemolytic anemia using therapeutic plasma exchange.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>549-557</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/vec.12876</ELocationID>\n            <Abstract>\n                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the successful management of acute bilirubin encephalopathy in a dog with immune-mediated hemolytic anemia (IMHA) treated with therapeutic plasma exchange (TPE) in conjunction with conventional medical management.</AbstractText>\n                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 6-year-old neutered male Australian Cattle Dog diagnosed with IMHA developed severe hyperbilirubinemia and stupor within the first 48 hours of implementing immunosuppressive therapy consisting of corticosteroids and mycophenolate. The patient received 4 blood transfusions during this period, but remained severely anemic PCV (18%) and experienced a subsequent increase in total bilirubin from 78 \xc2\xb5mol/L (4.6 mg/dL) to a peak value of 1,563 \xc2\xb5mol/L (91.4 mg/dL). The patient\'s neurological status rapidly deteriorated, resulting in lateral recumbency, vertical nystagmus, extensor rigidity, and stuporous mentation. Over the next 3 days, TPE was provided once every 24 hours, decreasing serum bilirubin, immunoglobulin G (IgG), and immunoglobulin M (IgM). The patient\'s red blood cell (RBC) transfusion requirements decreased immediately, requiring only 1 transfusion over the next 7 days that was required due to procedure-associated blood loss. Gradual neurological improvement was noted as serum bilirubin decreased. A brain magnetic resonance imaging (MRI) did not reveal any structural abnormalities and the patient was discharged after 11 days of hospitalization. Following discharge, the patient had complete remission of IMHA without any residual neurological deficits. Therapeutic plasma exchange played an integral role in case management and was successful in reducing bilirubin, IgG, and IgM.</AbstractText>\n                <AbstractText Label="NEW OR UNIQUE INFORMATION PROVIDED" NlmCategory="CONCLUSIONS">Bilirubin encephalopathy has been rarely reported in small animal medicine and cases have been limited to postmortem documentation. This is the first suspected case of acute bilirubin encephalopathy in a dog that survived and describes the clinical course of disease. The kinetics of serum bilirubin, IgG, and IgM concentrations before and after TPE and throughout the hospitalization period are also described.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 Veterinary Emergency and Critical Care Society 2019.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Heffner</LastName>\n                    <ForeName>Geoff G</ForeName>\n                    <Initials>GG</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0002-6112-4643</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, CO.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Alpenglow Veterinary Specialty and Emergency Center, Boulder, CO.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cavanagh</LastName>\n                    <ForeName>Amanda</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, CO.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Alpenglow Veterinary Specialty and Emergency Center, Boulder, CO.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Nolan</LastName>\n                    <ForeName>Benjamin</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Clinical Sciences, Colorado State University, Fort Collins, CO.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Alpenglow Veterinary Specialty and Emergency Center, Boulder, CO.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D002363">Case Reports</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>19</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Vet Emerg Crit Care (San Antonio)</MedlineTA>\n            <NlmUniqueID>101152804</NlmUniqueID>\n            <ISSNLinking>1476-4431</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D012709">Serum Albumin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>RFM9X3LJ49</RegistryNumber>\n                <NameOfSubstance UI="D001663">Bilirubin</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000744" MajorTopicYN="N">Anemia, Hemolytic, Autoimmune</DescriptorName>\n                <QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001663" MajorTopicYN="N">Bilirubin</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName>\n                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>\n                <QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004283" MajorTopicYN="N">Dog Diseases</DescriptorName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName>\n                <QualifierName UI="Q000662" MajorTopicYN="Y">veterinary</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012709" MajorTopicYN="N">Serum Albumin</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">anemia</Keyword>\n            <Keyword MajorTopicYN="N">canine</Keyword>\n            <Keyword MajorTopicYN="N">hyperbilirubinemia</Keyword>\n            <Keyword MajorTopicYN="N">plasmapheresis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2017</Year>\n                <Month>03</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2017</Year>\n                <Month>07</Month>\n                <Day>13</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2017</Year>\n                <Month>08</Month>\n                <Day>11</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31423707</ArticleId>\n            <ArticleId IdType="doi">10.1111/vec.12876</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>REFERENCES</Title>\n            <Reference>\n                <Citation>Piek C, Junius G, Dekker A, et\xc2\xa0al. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. Vet Intern Med. 2008;22:366-373.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 cases. J Vet Intern Med. 2002;16(5):504-509.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Weinkle TK, Center SA, Randolph JF, et\xc2\xa0al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc. 2005;226(11):1869-1880.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Grundy S, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc. 2001;218(4):543-546.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Goggs G, Dennis SG, Di Bella A, et\xc2\xa0al. Predicting outcome in dogs with primary immune-mediated hemolytic anemia: results of a multicenter case registry. J Vet Intern Med. 2015;29:1603-1610.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Harkin KR, Hicks JA, Wilkerson MJ. Erythrocyte-bound immunoglobulin isotypes in dogs with immune-mediated hemolytic anemia: 54 cases (2001-2010). J Am Vet Med Assoc. 2012;241:227-232.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Schwartz J, Winters JL, Padmanabhan A, et\xc2\xa0al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the sixth special issue. J Clin Apheresis. 2013;28:145-284.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Crump KL, Seshadri R. Use of therapeutic plasmapheresis in a case of canine immune-mediated hemolytic anemia. J Vet Emerg Crit Care. 2009;19(4):375-380.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Broux B, Lef\xc3\xa8re L, Deprez P, et\xc2\xa0al. Plasma exchange as a treatment for hyperbilirubinemia in 2 foals with neonatal isoerythrolysis. J Vet Intern Med. 2015;29:736-738.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Morioka I, Iwatani S, Koda T, et\xc2\xa0al. Disorders of bilirubin binding to albumin and bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med. 2015;20:31-36.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bhutani VK, Johnson-Maerman L. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med. 2015;20:6-13.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Rose J, Vassar R. Movement disorders due to bilirubin toxicity. Semin Fetal Neonatal Med. 2015;20:20-25.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Contreras ET, Giger U, Malmber JL, et\xc2\xa0al. Bilirubin encephalopathy in a domestic shorthair cat with increased osmotic fragility and cholangiohepatitis. Vet Pathol. 2016;53(3):629-632.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Belz KM, Specht AJ, Johnson VS. MRI findings in a dog with kernicterus. J Am Anim Hosp Assoc. 2013;49:286-292.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sangster CR, Stevenson CK, Kidney BA, et\xc2\xa0al. Kernicterus in an adult dog. Vet Pathol. 2007;44(3):383-385.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Polkes AC, Gigue`re S, Lester GD, et\xc2\xa0al. Factors associated with outcome in foals with neonatal isoerythrolysis (72 cases, 1988-2003). J Vet Intern Med. 2008;22(5):1216-1222.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Loynachan AT, Williams NM, Freestone JF. Kernicterus in a neonatal foal. J Vet Diagn Invest. 2007;19(2):209-212.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Williams ME, Balogun RA. Principles of separation: Indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol. 2014;9:181-90.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Keklik M, Sivgin S, Kaynar L, et\xc2\xa0al. Treatment with plasma exchange may serve beneficial effect in patients with severe hyperbilirubinemia: a single center experience. Transfus Apher Sci. 2013;48:323-326.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tse KC, Yip PS, Hui KM, et\xc2\xa0al. Potential benefit of plasma exchange in treatment of severe icteric leptospirosis complicated by acute renal failure. Clin Diagn Lab Immunol. 2002;9:482-484.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Landini S, Coli U, Lucatello S, et\xc2\xa0al. Plasma exchange in severe leptospirosis. Lancet. 1981;2:1119-1120.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tayama E, Kashikie H, Hayashida N, et\xc2\xa0al. Plasma exchange for hyperbilirubinemia following implantation of a left ventricle assist system: a case report. Jpn Circ J. 2000;64:455-458.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Saritas U, Aydin B, Ustundag Y. Plasmapheresis and corticosteroid treatment for persistent jaundice after successful drainage of common bile duct stones by endoscopic retrograde cholangiography. World J Gastroenterol. 2007;13(30):4152-4153.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Akdogan M, Camci C, Gurakar A, et\xc2\xa0al. The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher. 2006;21(2):96-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Maisels MJ, Baltz RD, Bhutani VK, et\xc2\xa0al. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297-316.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Fam Physician. 2014;89:873-878.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Khorzad R, Whelan M, Sisson A, et\xc2\xa0al. Myasthenia gravis in dogs with an emphasis on treatment and critical care management. J Vet Emerg Crit Care. 2011;21(3):193-208.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wisnowski JL, Panigrahy A, Painter JL, et\xc2\xa0al. Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. Semin Perinatol. 2014;38:422-428.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sar\xc4\xb1 S, Yavuz A, Batur A, et\xc2\xa0al. Brain magnetic resonance imaging and magnetic resonance spectroscopy findings of children with kernicterus. Pol J Radiol. 2015;80:72-80.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gamaleldin R, Iskander I, Seoud I, et\xc2\xa0al. Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia. Pediatrics. 2011;128:e925-e931.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Morioka I, Nakamura H, Koda T, et\xc2\xa0al. Serum unbound bilirubin as a predictor for clinical kernicterus in extremely low birth weight infants at a late age in the neonatal intensive care unit. Brain Dev. 2015;37:753-757.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'